重组带状疱疹疫苗在成人系统性红斑狼疮患者中的有效性和安全性:美国一项基于理赔数据的回顾性队列研究
该回顾性队列研究利用美国2018年1月1日至2023年9月30日的理赔数据,纳入18岁以上系统性红斑狼疮成人患者,比较接种两剂重组带状疱疹疫苗者与未接种者的带状疱疹发生率及严重狼疮 flare 风险。结果显示,在 Medicare 参保者中疫苗有效性为70%(95%CI 50%至82%),在商业保险参保者中为54%(95%CI 18%至74%);接种组严重 SLE flare 的 HR 分别为0.91(95%CI 0.75至1.11)和0.94(95%CI 0.72至1.24)。结论认为,重组带状疱疹疫苗可预防多数 SLE 患者的带状疱疹,且不增加严重 SLE flare 风险。
要点
- 在 Medicare 参保的 SLE 成人中,重组带状疱疹疫苗对带状疱疹的有效性为70%(95%CI 50%至82%)。
- 在商业保险参保的 SLE 成人中,重组带状疱疹疫苗对带状疱疹的有效性为54%(95%CI 18%至74%)。
- 接种重组带状疱疹疫苗后90天内严重 SLE flare 风险与未接种者相比无显著差异。
核心结论
- 重组带状疱疹疫苗可预防多数系统性红斑狼疮患者的带状疱疹,且不增加严重 SLE flare 风险。
研究设计与样本
- 回顾性队列研究,使用美国2018年1月1日至2023年9月30日的行政理赔数据,纳入18岁以上系统性红斑狼疮成人患者,分为 Medicare 参保队列和五家商业保险合作伙伴(含 Medicare Advantage 计划)参保队列。
- 疫苗有效性分析中,接受两剂重组带状疱疹疫苗(间隔≥28天)的成人按保险类型、性别和年龄(±5岁)以1:4匹配未接种对照,结局为31天后的带状疱疹发病。
- 安全性分析中,接受重组带状疱疹疫苗第1剂或第2剂的成人按上述方式匹配未接种对照,结局为90天内的严重 SLE flare。
- 采用 Cox 模型结合逆概率处理加权(IPTW)估计调整后的风险比(HR)。
主要发现
- 疫苗有效性队列包括2284例 Medicare 参保和1308例商业保险参保的重组带状疱疹疫苗接种患者,平均加权随访时间为1.4至1.6人年。
- 安全性队列包括 Medicare 参保者的6602剂次重组带状疱疹疫苗接种(第1剂或第2剂)和商业保险参保者的4196剂次接种。
- 逆概率处理加权后,接种与未接种患者的特征达到平衡。
- 疫苗有效性在 Medicare 参保者中为70%(95%CI 50%至82%),在商业保险参保者中为54%(95%CI 18%至74%)。
- 接种组与未接种组相比,严重 SLE flare 的 HR 在 Medicare 参保者中为0.91(95%CI 0.75至1.11),在商业保险参保者中为0.94(95%CI 0.72至1.24)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess vaccine effectiveness (VE) and safety of the recombinant zoster vaccine (RZV) in adults with systemic lupus erythematosus (SLE). METHODS: This retrospective study using administrative claims data collected between 1 January 2018 and 30 September 2023 from the USA included two cohorts of adults aged ≥18 years with SLE insured by (1) Medicare (parts A/B/D) or (2) one of five commercial partners (including Medicare Advantage plans). In VE analyses, adults receiving two RZV doses ≥28 days apart were matched 1:4 to unvaccinated comparators on insurer, sex and age (±5 years); the outcome was incident herpes zoster (HZ) after 31 days. In safety analyses, adults receiving RZV dose 1 or 2 were matched to unvaccinated comparators as above; the outcome was severe SLE flare within 90 days. Adjusted hazard ratios (HRs) were estimated using Cox models with inverse probability of treatment weighting (IPTW). RESULTS: VE cohorts included 2284 Medicare and 1308 commercially insured RZV-vaccinated patients; mean weighted follow-up was 1.4-1.6 person-years. Safety cohorts included 6602 RZV vaccinations (dose 1 or 2) in Medicare and 4196 in commercial insurers. Vaccinated versus unvaccinated patient characteristics were balanced after IPTW. VE was 70% (95% CI: 50% to 82%) in Medicare and 54% (95% CI: 18% to 74%) in commercially insured patients. The HR of severe SLE flare in vaccinated versus unvaccinated patients was 0.91 (95% CI: 0.75 to 1.11) in Medicare and 0.94 (95% CI: 0.72 to 1.24) in commercially insured patients. CONCLUSIONS: RZV prevented a majority of HZ cases in individuals with SLE without increasing the risk of severe SLE flare.
引用
- Mayer SE, Kluberg SA, Spence O, et al. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA. RMD Open. 2025. PMID: 40780731. doi:10.1136/rmdopen-2025-005839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。